AVITA Medical, Inc.
NASDAQ:RCEL · NASDAQ Capital Market
+$0.00 today
Vol 0.15M · Avg 0.24M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:RCEL · Revenue to Net Income
Key Ratios
Analysis
$72.3M of revenue converted into -$45.3M of net income for the selected period. Gross margin is 81.4% and net margin is -63.1%, showing how much revenue survives after costs and taxes. EPS is $-35.96, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.6M +11.5% | $64.3M +28.1% | $50.1M +45.7% | $34.4M +4.2% | $33.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $12.8M +40.7% | $9.1M +16.9% | $7.8M +28.8% | $6.0M -1.0% | $6.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $58.8M +6.6% | $55.2M +30.2% | $42.4M +49.3% | $28.4M +5.4% | $26.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 82.1% -3.7pp | 85.8% +1.4pp | 84.5% +2.0pp | 82.4% +0.9pp | 81.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $20.8M +2.4% | $20.4M -2.2% | $20.8M +50.3% | $13.9M -11.6% | $15.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $79.9M -12.6% | $91.4M +39.3% | $65.6M +45.1% | $45.2M +21.6% | $37.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $100.8M -9.8% | $111.8M +31.4% | $85.0M +52.1% | $55.9M +7.4% | $52.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.3M +108.4% | $1.1M +78.2% | $632.0K +11.3% | $568.0K -15.6% | $673.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$39.6M +28.4% | -$55.3M -64.9% | -$33.5M -28.8% | -$26.0M -6.7% | -$24.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -55.3% +30.8pp | -86.1% -19.2pp | -66.9% +8.8pp | -75.7% -1.8pp | -73.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$41.9M +25.9% | -$56.6M -32.7% | -$42.7M -55.1% | -$27.5M -9.5% | -$25.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -58.6% +29.5pp | -88.1% -3.0pp | -85.1% -5.2pp | -79.9% -3.9pp | -76.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.0M -6.7% | $5.4M +369.0% | $1.1M +7043.8% | $16.0K -44.8% | $29.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$6.6M -27.8% | -$5.2M -170.8% | $7.3M +737.9% | $876.0K +4766.7% | $18.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$48.6M +21.4% | -$61.8M -75.0% | -$35.3M -32.6% | -$26.6M -6.1% | -$25.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -67.8% +28.3pp | -96.2% -25.7pp | -70.4% +6.9pp | -77.4% -1.4pp | -76.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $11.0K -79.6% | $54.0K -18.2% | $66.0K +83.3% | $36.0K -14.3% | $42.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$48.6M +21.4% | -$61.8M -74.8% | -$35.4M -32.7% | -$26.7M -6.1% | -$25.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -67.8% +28.4pp | -96.3% -25.7pp | -70.6% +6.9pp | -77.5% -1.3pp | -76.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +27.2% | -$2 -70.7% | -$1 -30.8% | -$1 -3.9% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +27.2% | -$2 -70.7% | -$1 -30.8% | -$1 -3.9% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $27.9M +7.6% | $25.9M +2.2% | $25.3M +1.3% | $25.0M +2.6% | $24.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $27.9M +7.6% | $25.9M +2.2% | $25.3M +1.3% | $25.0M +2.6% | $24.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$306.63M
Shattuck Labs, Inc.
NASDAQ:STTK
$231.91M
Apyx Medical Corporation
NASDAQ:APYX
$170.43M
Quipt Home Medical Corp.
QIPT
$162.30M
Hyperfine, Inc.
NASDAQ:HYPR
$135.17M
FONAR Corporation
NASDAQ:FONR
$117.76M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$104.35M
Vivani Medical, Inc.
NASDAQ:VANI
$68.53M
Xtant Medical Holdings, Inc.
AMEX:XTNT
$61.01M
InspireMD, Inc.
NSPR
$33.26M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RCEL generate?
AVITA Medical, Inc. (RCEL) reported $71.61M of revenue in fiscal 2025.
Is RCEL profitable?
AVITA Medical, Inc. (RCEL) reported -$48,587,000.00 of net income, with a net margin of -67.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.